Published Technical Disclosure Archive

Intelligent Ocular Therapy Systems with Synergistic Combinations

Publication ID: 24-11857460_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Ocular Therapy Systems with Synergistic Combinations,” Published Technical Disclosure No. 24-11857460_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857460_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,460.

Summary of the Inventive Concept

The present inventive concept integrates patented ocular delivery systems with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to create a new generation of personalized, data-driven, and highly effective treatments for ocular diseases.

Background and Problem Solved

The original patent described innovative systems and methods for accessing Schlemm's canal in an eye and delivering a fluid composition therein. However, the original patent's methods and systems lacked the ability to leverage advanced technologies to enhance treatment outcomes, monitor patient data, and provide personalized therapy. The present inventive concept addresses these limitations by combining the patented ocular delivery systems with synergistic technologies to create a more powerful, data-driven, and personalized system.

Detailed Description of the Inventive Concept

The inventive concept disclosed herein combines the patented ocular delivery systems with AI-based image processing modules to guide the fluid delivery system, IoT-enabled wearable sensors to monitor intraocular pressure, blockchain-based data storage units to track treatment outcomes, nanomaterial-based coatings to enhance tissue disruption, machine learning algorithms to predict optimal treatment parameters, and genetic testing modules to identify genetic markers associated with glaucoma. These synergistic combinations enable real-time monitoring of treatment outcomes, personalized therapy, and data-driven decision-making.

Novelty and Inventive Step

The present inventive concept's novelty lies in the integration of patented ocular delivery systems with distinct technologies like AI, IoT, blockchain, and nanomaterials to create a new, more powerful system. The inventive step resides in the unexpected synergy between these technologies, which enables personalized, data-driven, and highly effective treatments for ocular diseases.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include the use of other advanced technologies like computer vision, robotics, or 3D printing to further enhance treatment outcomes. Variations may also include the application of the inventive concept to other ocular diseases or conditions beyond glaucoma.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the ophthalmology and healthcare industries, particularly in the areas of personalized medicine, data analytics, and digital health. The target market includes ophthalmologists, optometrists, and patients seeking advanced, data-driven treatments for ocular diseases.

CPC Classifications

SectionClassGroup
A A61 A61F9/0008
A A61 A61F9/00781
A A61 A61M5/002
A A61 A61M5/158
A A61 A61M5/3286
A A61 A61M5/3291
A A61 A61M2005/1585
A A61 A61M2210/0612

Field of Art

Ophthalmological medical devices and treatment systems, specifically focusing on intraocular fluid delivery, diagnostic imaging, and therapeutic interventions for glaucoma and related ocular conditions

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or medical device specialist with expertise in ophthalmological technologies, advanced sensor systems, minimally invasive surgical techniques, and interdisciplinary medical technology integration

Obviousness Rationale

A PHOSITA would recognize that integrating advanced digital technologies with existing ocular delivery systems represents a predictable and logical extension of the source patent's core mechanical fluid delivery approach. The combination of AI guidance, IoT monitoring, and data tracking with the fundamental ocular delivery mechanism would be considered an obvious implementation of known technological convergence strategies. The PTD's variations merely apply standard engineering practices of augmenting medical devices with contemporary digital monitoring and analytics capabilities.

Obvious Combinations & Variations

Source Patent Element
Cannula-based fluid delivery system for accessing Schlemm's canal
PTD Variation
Adding AI-based image processing module to guide fluid delivery system
Obviousness Reasoning
Integrating computer vision and guidance systems with medical devices is a well-established technique for improving precision and reducing human error in minimally invasive procedures
Source Patent Element
Elongate member for fluid delivery within ocular structures
PTD Variation
Applying nanomaterial-based coating to enhance tissue disruption
Obviousness Reasoning
Surface modification of medical devices using nanomaterials is a predictable approach for improving interaction with biological tissues, representing a standard design optimization strategy
Source Patent Element
Fluid delivery mechanism for treating ocular conditions
PTD Variation
Incorporating IoT-enabled wearable sensors to monitor intraocular pressure
Obviousness Reasoning
Adding real-time monitoring capabilities to medical devices is a known technique for improving patient outcomes and treatment effectiveness
Source Patent Element
Method for accessing and treating Schlemm's canal
PTD Variation
Implementing blockchain-based data storage for tracking treatment outcomes
Obviousness Reasoning
Applying distributed ledger technologies to medical record keeping represents a standard approach for improving data integrity and patient tracking
Source Patent Element
Fluid composition delivery for ocular treatment
PTD Variation
Integrating genetic testing modules to identify treatment-relevant genetic markers
Obviousness Reasoning
Personalized medicine approaches that correlate genetic information with treatment strategies are well-established in contemporary medical technology development
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857460 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed combinations of ocular delivery systems with digital monitoring, AI guidance, and personalized medicine technologies to be obvious extensions of the prior art, thereby rendering potential claims to such integrated systems unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,460
TitleOcular delivery systems and methods
Assignee(s)Sight Sciences, Inc.